Journal Watch · Science Translational Medicine · 2026
Chaperone-mediated autophagy supports organ regeneration and fibroblast quiescence in mouse models of fibrosis.
Thus, our study identifies LAMP2A as a broad-spectrum antifibrotic factor and provides proof of principle for dual targeting of core fibrotic cells to treat fibrosis.
TL;DR
Thus, our study identifies LAMP2A as a broad-spectrum antifibrotic factor and provides proof of principle for dual targeting of core fibrotic cells to treat fibrosis.
Key findings
- Moreover, pharmacological activation of CMA in these mouse models also alleviated organ fibrosis and promoted functional recovery when fibrosis had already been established.
- Thus, our study identifies LAMP2A as a broad-spectrum antifibrotic factor and provides proof of principle for dual targeting of core fibrotic cells to treat fibrosis.
What they did
In the three mouse models, recombinant adeno-associated virus-mediated overexpression of <i>Lamp2a</i> was sufficient to inhibit the initiation and progression of fibrosis. Mechanistically, we demonstrated that LAMP2A overexpression in cultured fibroblast cell lines and each of the three mouse models could suppress fibroblast activation and reverse established myofibroblast fates by directly degrading the mechanosensitive protein integrin subunit beta 1. In addition, through cell type-specific <i>Lamp2a</i> overexpression in these fibrotic mouse models, we found that LAMP2A could promote regeneration in the liver, lungs, and kidneys.
Full abstract (original)
Background: The core of organ fibrosis formation lies in the regenerative defects of parenchymal cells and in the excessive activation of fibroblasts, yet methods to simultaneously address these pathological cell types remain lacking. Here, we found that the expression of the chaperone-mediated autophagy (CMA) limiting factor lysosome-associated membrane protein type 2A (LAMP2A) was consistently down-regulated in mouse models of bleomycin-induced pulmonary fibrosis, carbon tetrachloride (CCl<sub>4</sub>)-induced liver fibrosis, and folic acid-induced renal fibrosis. We also confirmed a low CMA score in patients with idiopathic pulmonary fibrosis, renal fibrosis, systemic sclerosis, and myocardial fibrosis.
What they did: In the three mouse models, recombinant adeno-associated virus-mediated overexpression of <i>Lamp2a</i> was sufficient to inhibit the initiation and progression of fibrosis. Mechanistically, we demonstrated that LAMP2A overexpression in cultured fibroblast cell lines and each of the three mouse models could suppress fibroblast activation and reverse established myofibroblast fates by directly degrading the mechanosensitive protein integrin subunit beta 1. In addition, through cell type-specific <i>Lamp2a</i> overexpression in these fibrotic mouse models, we found that LAMP2A could promote regeneration in the liver, lungs, and kidneys.
Results & conclusions: Moreover, pharmacological activation of CMA in these mouse models also alleviated organ fibrosis and promoted functional recovery when fibrosis had already been established. Thus, our study identifies LAMP2A as a broad-spectrum antifibrotic factor and provides proof of principle for dual targeting of core fibrotic cells to treat fibrosis.
Abstract © the authors / Science Translational Medicine (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1126/scitranslmed.ads9597 · PubMed 41706873.
Why it matters for pharma & biotech
- Relevant to General & Medicine teams tracking Science Translational Medicine for new targets, mechanisms and biomarkers.
- Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Science Translational Medicine study find?
Thus, our study identifies LAMP2A as a broad-spectrum antifibrotic factor and provides proof of principle for dual targeting of core fibrotic cells to treat fibrosis.
What type of study is this?
It is a preclinical (animal / model) study, published in Science Translational Medicine in 2026. In the three mouse models, recombinant adeno-associated virus-mediated overexpression of <i>Lamp2a</i> was sufficient to inhibit the initiation and progression of fibrosis.
Where can I read the original paper?
The original is at the publisher via DOI 10.1126/scitranslmed.ads9597. PubMed ID: 41706873. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/chaperone-mediated-autophagy-supports-organ-regeneration-and-fibroblast-ds9597/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides